Determination and Pharmacokinetics of 6,7-Dimethoxycoumarin in Rat Plasma after Intragastric Administration of Different Decoctions of Yinchenhao Tang

Yu, Zhiguo; Wang, Qian; Li, Ke; Li, Yingqi; Gao, Xiaoxia

doi:10.1093/chromsci/45.8.544

Cited by 10 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After oral administration of DFD, the AUC 0– t , AUC 0–∞ and C max of BHA, BMA, BAC and HA decreased remarkably ( p < 0.05) compared with those of the FZ extract group. Although the results of absorption enhancement after combination owing to the competitive inhibition between components in herbs on P‐glycoprotein (P‐gp) or the inhibition against metabolism of CYP3A have been documented in many reports regarding to the comparative pharmacokinetics after combination (Wu et al ., 2009; Xu et al ., ; Xiao et al ., ; Yu et al ., ; Yan et al ., ; Tong et al ., 2010), quite a few studies have reported that absorption of effective components decreased after combination, especially for the combination regarding toxic herbs (Yan et al ., ; Wang et al ., ), which is in agreement with the results of our study. In addition, the T 1/2 values of BHA, BMA and BAC in DFD group were significantly delayed compared with those of the FZ extract group ( p < 0.05 for BHA, BMA; p < 0.01 for BAC), indicating that DFD could postpone the elimination of BHA, BMA and BAC in rats.…”

Section: Resultsmentioning

confidence: 99%

Comparative pharmacokinetics studies of benzoylhypaconine, benzoylmesaconine, benzoylaconine and hypaconitine in rats by LC‐MS method after administration of Radix Aconiti Lateralis Praeparata extract and Dahuang Fuzi Decoction

Liu

Song

et al. 2013

Biomedical Chromatography

View full text Add to dashboard Cite

A rapid and sensitive high-performance liquid chromatography-mass spectrometric (HPLC-MS) method was developed and validated for simultaneous determination of benzoylhypaconine (BHA), benzoylmesaconine (BMA), benzoylaconine (BAC) and hypaconitine (HA) in rat plasma for the first time. The analytes were separated on a Kromasil C₁₈ column with a total running time of 11 min. The validation data demonstrated a sound feasibility for the newly developed method and it was then applied to the pharmacokinetic study of these analytes in rats. Pharmacokinetic behaviors of BHA, BMA, BAC and HA in rats were studied after oral administration of Radix Aconiti Lateralis Praeparata extract (FZ) and Dahuang Fuzi Decoction (DFD). The main parameters for the two groups of subjects were compared, and significant differences between Radix Aconiti Lateralis Praeparata extract group and Dahuang Fuzi Decoction group in calculated parameters, such as the area under the plasma concentration-time from zero to the last quantifiable time-point (AUC(₀-t)), the area under the plasma concentration-time curve from zero to infinity (AUC(₀-∞)), peak plasma concentration (C(max)), half-life of elimination (T₁/₂), mean retention time (MRT(₀-t)), plasma clearance (CL), volume of distribution (V(d)) and time to reach Cmax (T(max)), were found. After oral administration of DFD, the AUC(₀-t), AUC(₀-∞) and C(max) of BHA, BMA, BAC and HA decreased remarkably (p < 0.05) compared with those of the FZ extract group. Vd and CL values of BHA, BMA, BAC and HA increased, two of which showed significant difference (p < 0.05). T₁/₂ and MRT(₀-t) values of BHA, BMA and BAC in the DFD group were significantly delayed compared with those of FZ extract group. Only the T(max) of HA, the toxic ingredient in FZ, delayed significantly in DFD group compared with the value of FZ group. All these pharmacokinetic parameters were statistically compared, and the rationality of the combination for DFD was clearly demonstrated.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparative pharmacokinetics studies of benzoylhypaconine, benzoylmesaconine, benzoylaconine and hypaconitine in rats by LC‐MS method after administration of Radix Aconiti Lateralis Praeparata extract and Dahuang Fuzi Decoction

Liu

Song

et al. 2013

Biomedical Chromatography

View full text Add to dashboard Cite

show abstract

“…Both CDCA and SC were assayed at 10 µM, a concentration that is widely used under laboratory conditions (Huang et al ., 2004; Kaimal et al ., 2009). The concentration of total bile acids in the blood in cholestasis ranges from 10 to 30 µM (Brites et al ., 1998), and it is estimated that SC reaches 10–20 µM in the liver after oral administration; this is based on a pharmacokinetic study in rats (Yu et al ., 2007). As expected, CDCA efficaciously increased BSEP but had little effect on CYP2B6 or UGT1A1 (Figure 1C).…”

Section: Resultsmentioning

confidence: 99%

Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor

Yang

Shi

et al. 2011

British Journal of Pharmacology

View full text Add to dashboard Cite

BACKGROUND AND PURPOSE Hyperbilirubinaemia and cholestasis are two major forms of liver abnormality. The Chinese herb Yin Chin has been used for thousands of years to treat liver dysfunctions. In mice, this herb and its principal ingredient scoparone were found to accelerate the clearance of bilirubin accompanied by the induction of uridine diphosphate‐5′‐glucuronosyltransferase‐1A1 (UGT1A1), a bilirubin processing enzyme. The aim of this study was to determine whether scoparone induces the expression of human UGT1A1. In addition, the expression of the bile salt export pump (BSEP), a transporter of bile acids, was determined. EXPERIMENTAL APPROACH Primary human hepatocytes and hepatoma line Huh7 were treated with scoparone, chenodeoxycholic acid (CDCA) or both. The expression of UGT1A1 and BSEP mRNA was determined. The activation of the human BSEP promoter reporter by scoparone was determined in Huh7 cells by transient transfection and in mice by bioluminescent imaging. The metabolism of scoparone was investigated by recombinant CYP enzymes and pooled human liver microsomes. KEY RESULTS Scoparone did not enhance the expression of either human BSEP or, surprisingly, UGT1A1. However, scoparone significantly potentiated the expression of BSEP induced by CDCA. Consistent with this, scoparone potentiated the stimulant effect of CDCA on the human BSEP promoter. This potentiation was enhanced by co‐transfection of cytochrome P4501A2 but abolished by the PKC inhibitor GF109203X. CONCLUSIONS AND IMPLICATIONS Scoparone and Yin Chin normalize liver function primarily by enhancing the secretion of bile acids, and this effect probably varies depending on the metabolic rate of scoparone.

show abstract

“…To date, several publications are available on the pharmacokinetic properties of the above 1-3 active components in YCHT in healthy rats [ 2 , 9 , 23 – 25 ]. However, researchers have presented that chemicals' pharmacokinetic profile may be influenced by liver disease, such as liver fibrosis [ 26 , 27 ] and nonalcoholic fatty liver disease [ 28 ].…”

Section: Introductionmentioning

confidence: 99%

Development and Application of an UHPLC‐MS/MS Method for Comparative Pharmacokinetic Study of Eight Major Bioactive Components from Yin Chen Hao Tang in Normal and Acute Liver Injured Rats

Wang

Xing

Cao

et al. 2018

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Yin Chen Hao Tang (YCHT) is one of the most famous hepatoprotective herbal formulas in China, but its pharmacokinetic investigation in model rats has been rarely conducted. In this study, the hepatic injury model was caused by intraperitoneal injections of carbon tetrachloride (CCl4), and YCHT was orally administered to the model and normal rats. An ultrahigh performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) method was established to analyze the plasma pharmacokinetics of eight major bioactive ingredients from YCHT in both the normal and liver injured rats. The calibration curves presented good linearity (r > 0.9981) in the concentration range. The relative standard deviation (RSD%) of inter- and intraday precision was within 9.55%, and the accuracy (RE%) ranged from -10.72% to 2.46%. The extraction recovery, matrix effect, and stability were demonstrated to be within acceptable ranges. The lower limit of detection (LLOD) and lower limit of quantitation (LLOQ) were around 0.1 ng/mL and 0.5 ng/mL, respectively, which were much lower than those in other related researches. Results reveal that there are significant differences in the pharmacokinetics of scoparone, geniposide, rhein, aloe-emodin, physcion, and chrysophanol in hepatic injured rats as compared to those in control except for scopoletin and emodin. Our experimental results provide a meaningful reference for the clinical dosage of YCHT in treating liver disorders, and the improvement of LLOD and LLOQ can also broaden the range of our method's application, which is very suitable for quantitating these eight compounds with low levels.

show abstract

Determination and Pharmacokinetics of 6,7-Dimethoxycoumarin in Rat Plasma after Intragastric Administration of Different Decoctions of Yinchenhao Tang

Cited by 10 publications

References 5 publications

Comparative pharmacokinetics studies of benzoylhypaconine, benzoylmesaconine, benzoylaconine and hypaconitine in rats by LC‐MS method after administration of Radix Aconiti Lateralis Praeparata extract and Dahuang Fuzi Decoction

Comparative pharmacokinetics studies of benzoylhypaconine, benzoylmesaconine, benzoylaconine and hypaconitine in rats by LC‐MS method after administration of Radix Aconiti Lateralis Praeparata extract and Dahuang Fuzi Decoction

Scoparone potentiates transactivation of the bile salt export pump gene and this effect is enhanced by cytochrome P450 metabolism but abolished by a PKC inhibitor

Development and Application of an UHPLC‐MS/MS Method for Comparative Pharmacokinetic Study of Eight Major Bioactive Components from Yin Chen Hao Tang in Normal and Acute Liver Injured Rats

Contact Info

Product

Resources

About